Clinical Trial Update: Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for IDEAL trial evaluating innate donor effector allogeneic lymphocyte infusion after stem cell transplantation in AML/MDS, currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Innate donor effector allogeneic lymphocyte infusion

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: AML/MDS | Phase 2, Phase 3 | Status: RECRUITING